# DOCUMENT 8: INFECTION AFTER TRANSPLANTATION - PREVENTION AND MANAGEMENT

## Executive Summary

Infection is among the most common complications post-transplantation, occurring in 40-90% of recipients depending on organ type, immunosuppression intensity, and prophylaxis strategies. Post-transplant infections encompass viral (CMV, EBV, polyomavirus), bacterial, fungal, and parasitic organisms, each with distinct epidemiology, timing, and clinical manifestations. Early prevention through prophylaxis, monitoring, and preemptive therapy is critical to minimize mortality and morbidity. This document comprehensively addresses infection epidemiology, risk stratification, prophylactic strategies, monitoring approaches, and management of major post-transplant pathogens across solid organ transplantation.

---

## 1. EPIDEMIOLOGY AND RISK FACTORS

### 1.1 Timing of Infection Post-Transplant

Post-transplant infections follow predictable temporal patterns based on degree of immunosuppression:

**0-1 month (Immediate period):**
- **Infections common in non-transplant surgery:** Surgical site infections, line infections, aspiration pneumonia
- **Sources:** Donor-transmitted (from contaminated organs), operatively acquired
- **Organisms:** Bacterial (S. aureus, Streptococcus, Gram-negatives), fungal (Candida from respiratory colonization)
- **Immunosuppression:** Maximal (induction therapy ongoing)

**1-4 months (Early "at-risk" period):**
- **Peak period for opportunistic infections**
- **CMV disease:** 30-50% without prophylaxis (D+R− > D+R+ > D−R+ > D−R−)
- **Opportunistic organisms:** PCP, cryptococcal meningitis, Aspergillus, toxoplasmosis
- **EBV reactivation and early PTLD:** EBV-seronegative recipients at highest risk
- **Polyomavirus (BK, JC):** BK viremia common; BK-associated nephropathy (BKVAN) can develop
- **Immunosuppression:** Still maximal; induction therapy completed

**>4-12 months (Intermediate period):**
- **Declining immunosuppression** (doses being minimized)
- **CMV disease declining** (if prophylaxis stopped)
- **Chronic viral infections:** BK virus, EBV (PTLD), HCV
- **Community-acquired:** Influence, respiratory viruses in winter months
- **Immunosuppression:** Approaching maintenance levels

**>1 year (Late period):**
- **Infections similar to immunocompetent population** (if good graft function, maintenance IS)
- **Community-acquired infections:** Influenza, pneumonia, UTI, etc.
- **Chronic viral:** Continued BK, EBV monitoring
- **Recurrent/relapsing infections:** If chronic conditions (CMV, TB reactivation)
- **Immunosuppression:** Maintenance levels (minimal)

### 1.2 Risk Stratification

**High-risk recipients for infection:**
1. **Degree of immunosuppression:**
   - Induction with lymphocyte-depleting agents (rATG, alemtuzumab) → higher risk
   - High CNI levels
   - Addition of second antiproliferative agent

2. **Organ type:**
   - Intestine transplant: Highest risk
   - Heart/lung: Very high risk
   - Kidney/liver: Moderate-high risk

3. **Donor factors:**
   - CMV seropositivity (D+)
   - Severe illness or prolonged ICU stay (bacterial colonization, aspiration)
   - Herpes simplex seropositivity
   - Hepatitis B or C (if transmitted)

4. **Recipient factors:**
   - CMV seropositivity status (D+R− at highest risk)
   - EBV seropositivity status (EBV-negative at risk for severe disease)
   - Diabetes mellitus
   - Obesity
   - Advanced age
   - Dialysis patients (immune dysfunction)
   - Repeat transplant recipients
   - Non-adherence to medications

5. **Environmental/epidemiologic:**
   - Seasonal (influenza/respiratory viruses in winter)
   - Geographic (endemic fungi: Histoplasma in Ohio River valley, Coccidioides in Southwest)
   - Healthcare-associated (hospital stays, line infections)

---

## 2. PROPHYLACTIC STRATEGIES

### 2.1 Bacterial Infection Prophylaxis

**Surgical site infection prophylaxis (perioperative):**
- **Timing:** Within 120 minutes preoperatively (60 minutes for vancomycin/clindamycin)
- **Duration:** Discontinue within 24 hours (48 hours for cardiac surgery)
- **Agents:** Cephalosporin (typical: cefazolin) or clindamycin (if penicillin allergy)
- **Dosing:** Weight-based; redose if prolonged surgery

**Urinary tract infection prophylaxis:**
- **Foley catheter:** Remove at 48-72 hours post-transplant (reduces catheter-associated UTI)
- **Early mobilization:** Helps bladder emptying
- **Hydration:** Maintains urine output
- **Prophylactic antibiotics:** Generally NOT recommended (promotes resistance; use only if symptoms)

**Bacterial endocarditis prophylaxis:**
- **Indication:** Cardiac transplant recipients with native aortic valve disease
- **Agents:** Amoxicillin or clindamycin for dental/GI procedures
- **Dental care:** Important for oral health

---

### 2.2 Viral Prophylaxis and Monitoring

#### CMV Prophylaxis (Cytomegalovirus)

**Risk stratification:**
- **D+R−** (donor CMV+, recipient CMV−): Highest risk (~30-50% without prophylaxis)
- **D+R+, D−R+:** Intermediate risk (~10-20%)
- **D−R−:** Lowest risk (<5%)

**Prophylactic agents:**

| Agent | Dose | Duration | Pros/Cons |
|-------|------|----------|-----------|
| **Valganciclovir** | 900 mg daily (adjusted for renal function) | 3-4 months (D+R−); 1-3 months (D+R+) | Most common; oral; well tolerated; bone marrow suppression risk |
| **Ganciclovir IV** | 5 mg/kg BID (adjusted for renal function) | 2-4 weeks → conversion to valganciclovir | For patients unable to take PO; more toxic |
| **Acyclovir/Valacyclovir** | Acyclovir: 800 mg 4-5×/day; Valacyclovir: 1-2 g QID | 3-6 months | Weaker CMV suppression; mainly HSV/VZV coverage; lower cost |
| **Foscarnet** | 90 mg/kg BID | Alternative (toxicity, renal) | For ganciclovir-resistant strains; nephrotoxic |
| **Cidofovir** | 5 mg/kg weekly × 2 weeks | Alternative (rare) | Nephrotoxic; limited use |

**Mechanism:**
- Inhibit viral DNA polymerase
- Prevent viral replication; don't eliminate latent virus
- Stop at end of prophylaxis period; risk of reactivation

**Adverse effects:**
- **Valganciclovir:** Neutropenia (dose-dependent; monitor CBC), thrombocytopenia, anemia
- **Ganciclovir IV:** Venoocclusive disease, CNS toxicity
- **Acyclovir:** Neurotoxicity (tremor, confusion; rare)

**Monitoring during prophylaxis:**
- CBC: Baseline, then every 1-2 weeks (monitor for neutropenia)
- CMV antigen (pp65) or CMV PCR: NOT routinely done during effective prophylaxis (would be negative)

#### CMV Preemptive Therapy

**Alternative to prophylaxis (used in some centers):**
- No routine prophylaxis given
- Frequent CMV monitoring (weekly CMV antigen or PCR)
- **Preemptive therapy:** When CMV detected (before symptoms), treat with valganciclovir or IV ganciclovir

**Rationale:** Reduce unnecessary prophylaxis; treat only those who develop viremia

**Challenges:**
- Requires frequent monitoring (compliance issues)
- Risk of missing CMV disease if viremia progresses rapidly
- May miss tissue-invasive CMV (lower viremia load)

**Current trend:** Most centers prefer prophylaxis (safer, more reliable) over preemptive therapy

#### CMV Treatment (Symptomatic Disease/Syndrome)

**Presentations:**
- **CMV syndrome:** Fever, malaise, atypical lymphocytosis, leukopenia, thrombocytopenia (viremia, not tissue invasion)
- **CMV pneumonia:** Bilateral infiltrates, hypoxemia, respiratory symptoms
- **CMV colitis/esophagitis:** Diarrhea, abdominal pain, dysphagia
- **CMV retinitis:** Floaters, photopsia, visual field changes (ophthalmologic emergency)
- **CMV hepatitis:** Elevated transaminases

**Treatment:**
- **Ganciclovir IV:** 5 mg/kg BID × 2-3 weeks
- **Valganciclovir:** 900 mg BID × 2-3 weeks (if able to take PO; GI disease contraindication)
- **Foscarnet:** For ganciclovir-resistant strains (rare; HSV/CMV resistant mutants)
- **Cidofovir:** Alternative for resistant strains (nephrotoxic)

**Monitoring during treatment:**
- Repeat CMV antigen/PCR in 1-2 weeks (document clearance)
- CBC: Monitor for neutropenia (may require dose reduction)
- Renal function: GFR; all agents nephrotoxic
- Clinical response: Symptoms improvement, vital signs

**Duration:** Typically 2-3 weeks; longer if severe disease

#### Herpes Simplex Virus (HSV) Prophylaxis

**Epidemiology:**
- Incidence of reactivation: 10-30% without prophylaxis
- Presentation: Mucocutaneous vesicles (lips, genitals, perirectal)
- Severe disease: Esophagitis, pneumonia, disseminated

**Prophylaxis agents:**
- **Acyclovir:** 400-800 mg 2-4×/day (combined with CMV prophylaxis coverage)
- **Valacyclovir:** 500 mg BID
- **Duration:** 4-12 weeks (often until CMV prophylaxis stopped)

**Treatment (symptomatic):**
- **Acyclovir IV:** 10 mg/kg Q8h (for severe/disseminated)
- **Acyclovir PO:** 400-800 mg 4-5×/day (for mucocutaneous)
- **Duration:** 7-10 days

---

### 2.3 Fungal Prophylaxis

**Candida Prophylaxis:**
- **Indications:** High-risk recipients (heavy immunosuppression, repeat transplant, diabetes)
- **Agents:** Fluconazole 200-400 mg daily
- **Duration:** 2-4 weeks post-transplant
- **Mechanism:** Azole inhibits ergosterol synthesis in fungal cell membrane

**PCP (Pneumocystis jirovecii) Prophylaxis:**
- **Indication:** ALL transplant recipients (universal recommendation)
- **First-line:** Trimethoprim-sulfamethoxazole (TMP-SMX)
  - Dosing: Single-strength or double-strength daily (provides coverage for PCP + some bacterial + Toxoplasma)
  - Duration: Lifelong (or until CD4 recovery if ever significantly depressed)
  - Advantages: Broad coverage; cost-effective
  
- **Alternative (if TMP-SMX intolerance):** Pentamidine inhaled monthly, or atovaquone + azithromycin
- **Efficacy:** Highly effective; PCP now rare in transplant population

**Toxoplasmosis Prophylaxis:**
- **Indication:** Toxoplasma-seropositive recipients (T+) at risk for reactivation
- **Prevention:** TMP-SMX coverage (provides prophylaxis)
- **Treatment (if encephalitis develops):** Pyrimethamine + sulfadiazine + folinic acid

**Aspergillosis Prophylaxis:**
- **Indications:** Selective (high-risk recipients, invasive procedure, severe immunosuppression)
- **Agents:** Inhaled or systemic antifungal (itraconazole, voriconazole, posaconazole)
- **Duration:** Variable (2-4 weeks or longer)
- **Efficacy:** Reduces incidence in high-risk groups

---

### 2.4 Parasitic Prophylaxis

**Strongyloides hyperinfection syndrome prophylaxis:**
- **Indication:** Strongyloides-seropositive recipients (endemic areas: Southern US, Africa, Asia)
- **Screening:** Strongyloides serology before transplantation
- **Treatment (if seropositive):** Ivermectin 2 doses (before transplant or early post-tx)

**Malaria prophylaxis:**
- **Indication:** Transplant recipients from or traveling to endemic areas
- **Agent:** Chloroquine ± primaquine (depending on plasmodium species)

---

## 3. MONITORING STRATEGIES

### 3.1 Viral Monitoring

**CMV monitoring:**
- **During prophylaxis:** Not routinely needed (should be undetectable)
- **If symptoms develop:** CMV antigen (pp65) or quantitative CMV PCR
- **Post-prophylaxis:** Monthly monitoring in first year (if stopping prophylaxis)
- **Threshold for preemptive treatment:** Variable by center; typically if CMV >1,000 copies/mL

**EBV monitoring:**
- **Baseline:** EBV serology (IgG, IgM)
- **Risk assessment:** EBV-seronegative recipients higher risk for severe PTLD
- **Monitoring:** EBV PCR (quantitative) at baseline, 1-2 months, 3 months, then periodically
- **Risk stratification:** Rising EBV load → intensify monitoring, consider reduction of IS
- **Threshold for intervention:** Variable; some centers preempt with rituximab if EBV >50,000 copies/mL

**BK polyomavirus monitoring (kidney):**
- **Baseline:** Baseline BK serology (only identifies prior exposure, not risk)
- **Monitoring:** BK PCR (plasma/urine) at 1, 3, 6, 12 months then periodically
- **Risk stratification:** Increasing BK load → risk for BKVAN
- **Thresholds:** Plasma BK >100,000 copies/mL indicates high risk; urine BK PCR less specific
- **Intervention:** Reduce IS, minimize CNI when BK >100,000; switch CNI if possible; monitor with allograft biopsy if creatinine rising

**JC polyomavirus monitoring:**
- **Less common than BK** in kidney
- **PML risk:** JC reactivation → progressive multifocal leukoencephalopathy (CNS disease)
- **Monitoring:** JC PCR if neurologic symptoms develop
- **Management:** Reduce IS aggressively; very high mortality if PML develops

**HIV monitoring:**
- **Status:** Transplantation in HIV+ recipients now common (HIV+ to HIV+ transplant)
- **Monitoring:** CD4 count, viral load at baseline, periodically post-transplant
- **Goal:** Maintain CD4 >200 cells/μL (similar to non-transplant HIV management)

---

### 3.2 Bacterial/Fungal Monitoring

**Cultures:**
- **Not routinely screened** (colonization vs. infection unclear)
- **Taken when symptoms suggest infection:** Blood cultures (fever), urine cultures (dysuria), respiratory cultures (cough)

**Surveillance cultures:**
- **Respiratory secretions/throat:** Only if concerned about Aspergillus/invasive mold (not routine)
- **Stool/urine:** Not routinely recommended

---

## 4. MANAGEMENT OF SPECIFIC INFECTIONS

### 4.1 Bacterial Infections

**Urinary tract infection (UTI):**
- **Diagnosis:** Urinalysis + culture; symptoms (dysuria, frequency, suprapubic pain) or asymptomatic bacteriuria
- **Treatment:** Oral fluoroquinolone (ciprofloxacin 500 mg BID) or TMP-SMX (if susceptible); course 7-10 days
- **Asymptomatic bacteriuria:** Treat (unlike general population) due to immunosuppression and graft risk

**Pneumonia (bacterial):**
- **Diagnosis:** CXR infiltrates, sputum or BAL culture
- **Organisms:** Community-acquired (S. pneumoniae, H. influenzae) vs. healthcare-associated (P. aeruginosa, MRSA, Acinetobacter)
- **Treatment:** Empiric broad-spectrum pending culture
  - Community-acquired: Fluoroquinolone or beta-lactam + macrolide
  - Healthcare-associated: Anti-pseudomonal beta-lactam + aminoglycoside ± fluoroquinolone
- **Duration:** 10-14 days (adjust if immunosuppression allows)

**Blood stream infections (BSI):**
- **Source:** Line infection (central line), UTI, intra-abdominal, other
- **Diagnosis:** Blood cultures (2 sets) + clinical signs (fever, hypotension)
- **Treatment:** Empiric broad-spectrum IV antibiotics pending culture
  - Remove central line if infected
  - Source control (drainage if abscess, etc.)
- **Duration:** 7-14 days (depending on source, organism)

---

### 4.2 Fungal Infections

**Candida (invasive):**
- **Risk factors:** Prolonged antibiotic use, central lines, diabetes, severe immunosuppression
- **Diagnosis:** Blood cultures, imaging (if disseminated)
- **Treatment:** IV fluconazole or caspofungin
  - Fluconazole: 400-600 mg daily (if susceptible)
  - Caspofungin: 50-70 mg daily (if fluconazole-resistant or CNS involvement suspected)
- **Duration:** 14-21 days (adjust if disseminated)

**Aspergillus (invasive):**
- **Presents:** Pulmonary nodules/infiltrates, sinusitis, disseminated
- **Diagnosis:** CT imaging, BAL with cultures/antigen, blood antigen (galactomannan; some centers)
- **Treatment:** Voriconazole 6 mg/kg IV Q12h × 1 day, then 4 mg/kg Q12h (preferred agent)
  - Alternative: Caspofungin, posaconazole, liposomal amphotericin B
- **Duration:** 6-12 weeks minimum (or longer if disseminated)

**Cryptococcus:**
- **Presents:** Meningitis (headache, fever, meningeal signs), pulmonary infection
- **Diagnosis:** CSF analysis (India ink, cryptococcal antigen), blood/urine antigen
- **Treatment:** 
  - Induction: Amphotericin B IV 0.7-1 mg/kg daily × 2 weeks
  - Consolidation: Fluconazole 400-600 mg daily × 8 weeks
  - Maintenance: Fluconazole 200-400 mg daily × 6-12 months
- **Prognosis:** Meningitis carries high mortality even with treatment

---

## 5. SPECIAL POPULATIONS AND SCENARIOS

### 5.1 EBV-Seronegative Recipients

**Risk:** Severe primary EBV infection post-transplant; risk for early aggressive PTLD

**Management:**
- **Baseline testing:** EBV serology; confirm seronegative (no IgG)
- **Monitoring:** EBV PCR monthly × 3 months, then every 3 months × 1 year
- **Precautions:** Minimize immunosuppression intensity if possible
- **Intervention:** If EBV PCR rises markedly or PTLD suspected:
  - Reduce IS (halve CNI, stop antimetabolite)
  - Consider rituximab (early PTLD prevention)
  - Urgent biopsy if nodal symptoms

### 5.2 CMV-Seronegative Recipients Receiving CMV+ Donor Organ (D+R−)

**Risk:** Highest-risk group for CMV disease (~30-50%)

**Management:**
- **Prophylaxis mandatory:** Valganciclovir 900 mg daily × 3-4 months (NOT preemptive therapy)
- **Monitoring:** Less frequent during prophylaxis (only if symptoms)
- **Duration:** Extended prophylaxis (4 months vs. 1-3 months for others)

### 5.3 Drug-Resistant Organisms

**Resistant CMV:**
- **Risk factors:** Prolonged immunosuppression, prior ganciclovir exposure
- **Diagnosis:** Viral culture with resistance testing; clinical failure of ganciclovir
- **Management:** Switch to foscarnet or cidofovir
- **Prevention:** Limit unnecessary ganciclovir exposure; adhere to prophylaxis regimens

**BK-resistant to reduction of IS:**
- **Challenge:** BKVAN despite IS reduction
- **Options:** Switch CNI, add adjunctive agents (cidofovir, leflunomide, IVIG), increase monitoring

---

## 6. SUMMARY AND KEY CONCEPTS

1. **Timing of infection predictable:** Early period (0-4 months) = peak opportunistic risk

2. **Prophylaxis critical:** CMV prophylaxis, PCP prophylaxis, and surgical prophylaxis standard

3. **Risk stratification essential:** D+R− CMV-highest risk; EBV-seronegative highest PTLD risk

4. **Monitoring strategies:** CMV, EBV, BK, Strongyloides, others based on risk factors

5. **Early detection and treatment:** Preemptive therapy (especially CMV, EBV, BK) prevents progression

6. **Immunosuppression balance:** Must maintain IS for graft while managing infection

7. **Multidisciplinary approach:** Infectious disease, transplant surgery, organ-specific teams collaborate

---

**Document Version:** 1.0  
**Evidence Base:** AST Guidelines, CDC/IDSA, Peer-Reviewed Literature (2020-2025)

